GIP as a potential therapeutic agent?

Hormone and Metabolic Research

Volumn 36, Issue 11-12, 2004, Pages 859-866

  Meier, J J ^a   Nauck, M A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Gastric inhibitory polypeptide; GIP; Insulin secretion; Obesity; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR AGONIST; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

FOOD INTAKE; HORMONE RELEASE; HUMAN; INSULIN RELEASE; KILLER CELL; KNOCKOUT MOUSE; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

ADIPOSE TISSUE; ANIMALS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; OBESITY; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 12244270387     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826176     Document Type: Review

References (118)

1. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209: 57-64
2. Brown JC, Dryburgh JR. A gastric inhibitory polypeptide II. The complete amino acid sequence. Can J Biochem 1971; 49: 867-872
3. Brown JC. A Gastric Inhibitory Polypeptide. I. The amino acid composition and the tryptic peptides. Can J Biochem 1971; 49: 255-261
4. Pederson RA, Brown JC. Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure 'gastric inhibitory polypeptide'. Gastroenterology 1972; 62: 393-400
5. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects. Digestion 1992; 52: 214-221
6. Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE et al. Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. Am J Physiol (Endocrinol Metab) 2004; 286: E621-E625
7. Dupré J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828
8. Siegel EG, Creutzfeldt W. Stimulation of insulin release in isolated rat islets by GIP in physiological concentrations and its relation to cyclic AMP content. Diabetologia 1985; 28: 857-861
9. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas. Endocrinology 1976; 99: 780-785
10. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocrine Reviews 1988; 9: 122-133
11. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498
12. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas. Endocrinol 1978; 103: 610-615
13. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798-801
14. O'Harte FP, Gray AM, Flatt PR. Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol 1998; 156: 237-243
15. Service FJ, Heiling VJ, Go VLW, Rizza RA. Lack of effect of gastric inhibitory polypeptide on hepatic and extrahepatic insulin action. J Clin Endocrinol Metab 1990; 70: 1398-1402
16. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhance lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979; 28: 1141-1142
17. Beck B, Max JP. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat. Regul Pept 1983; 7: 3-8
18. Beck B, Max JP. Hypersensitivity of adipose tissue to gastric inhibitory polypeptide action in obese Zucker rat. Cell Mol Biol 1987; 33: 555-562
19. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991; 130: 267-272
20. Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Linger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 1981; 68: 1107-1110
21. Kindmark H, Pigon J, Efendic S. Glucose-dependent insulinotropic hormone potentiates the hyopglyacemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab 2001; 86: 2015-2019
22. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE et al. The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric Inhibitory polypeptide (GIP). Regul Peptides 2003; 113: 95-100
23. Holst JJ. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1? BioDrugs 2002; 16: 175-181
24. Kieffer TJ. GIP or not GIP? That is the question. Trends Pharmacol Sci 2003; 24: 110-112
25. Gault VA, Flatt PR, O'Harte FP. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003; 308: 207-213
26. Gault VA, O'Harte FP, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003; 37: 253-263
27. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 1999; 48: 758-765
28. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Dernuth HU et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002; 51: 652-661
29. Gault VA, Harriott P, Flatt PR, O'Harte FPM. GIP analogues substituted at Ala2 exhibit improved plasma stability and insulin-releasing activity (abstract). Diabetologia 2001; 44 (Suppl. 1): A195
30. Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, Mooney MH et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J 2002; 367: 913-920
31. Gault VA, Irwin N, Harriott P, Flatt PR, O'Harte FP DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP. Cell Biol Int 2003; 27: 41-46
32. Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ, O'Harte FP. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J Endocrinol 2003; 176: 133-141
33. Gault VA, O'Harte FP, Harriott P, Flatt PR. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism 2003; 52: 679-687
34. O'Harte FP, Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 2002; 45: 1281-1291
35. Gault VA, O'Harte FP, Harriott P, Flatt PR. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 2002; 290: 1420-1426
36. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742
37. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082
38. Shuster LT, Go VLW, Rizza RA, O'Brien PC, Service FJ. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes 1988; 37: 200-203
39. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85
40. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28: 565-573
41. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-54
42. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes/Metab Rev 1992; 8: 149-177
43. Amland PF, Jorde R, Aanderup S, Burhol PG, Giercksky K-E. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 1985; 20: 315-320
44. Jorde R, Burhol PG. The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes. Ital J Gastroenterol 1987; 19: 76-78
45. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on β-cell function in Type I and Type II diabetes mellitus. Metabolism 1988; 36: 677-682
46. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307
47. Meier JJ, Hücking K, Holst JJ, Deacon C, Schmiegel W, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-2504
48. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-1119
49. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilstred LM, Hughes TE, Michelsen BK et al. Determinants of impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723
50. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613
51. Crockett SE, Mazzaferri EL, Cataland S. Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus. Diabetes 1976; 25: 931-935
52. Ross SA, Brown JC, Dupré J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 1977; 26: 525-529
53. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 668-677
54. Amlind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ et al. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell response and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 1998; 41: 1194-1198
55. Kubota A, Yamada Y, Hayami T, Yasuda K, Ihara Y, Kagimoto S et al. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 1996; 45: 1701-1705
56. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 1997; 40: 984-986
57. Lynn PC, Pamir N, Ng EH, McIntosh CH, Kieffeŕ TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-1011
58. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N et al. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. Faseb J 2003; 17: 91-93
59. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide (GIP): the neglected incretin revisited. Regul Peptides 2002; 107: 1-13
60. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
61. Siegel EG, Schulze A, Schmidt WE, Creutzfeldt W. Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets. Eur J Clin Invest 1992; 22: 154-157
62. Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes 1975; 24: 1050-1056
63. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci 1999; 96: 14843-14847
64. Elahi D, Raizes GS, Andres R, Hershcopf RJ, Muller DC, Tobin JD et al. Interaction of arginine and gastric inhibitory polypeptide on insulin release in man. Am J Physiol 1982; 242: E343-E351
65. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917
66. Meier JJ, Nauck MA, Siepmann N, Greulich M, Holst JJ, Deacon CF et al. Similar insulin secretory response to a GIP bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003; 52: 1579-1585
67. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man; interactions with glucose, phenylalanine, and cholezystokinin-8. J Clin Endocrinol Metab 1989; 69: 654-662
68. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-;36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725
69. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377
70. Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001; 15: 1559-1570
71. Trümper A, Trümper K, Horsch D. Mechanisms of mitogenic and antiapoptotic signalling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002; 174: 233-246
72. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D et al. Secretion, degradation, and elimination of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in patients with chronic renal insufficiency and healthy controls. Diabetes 2004; 53: 654-662
73. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835
74. Deacon CF, Nauck MA, Meier JJ, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581
75. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002; 175: 525-533
76. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 1987; 30: 707-712
77. May JM, Williams RH. The effect of endogenous Gastric Inhibitory Polypeptide on glucose-induced insulin secretion in mild diabetes. Diabetes 1978; 27: 849-855
78. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744
79. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2719-2725
80. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-2013
81. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673
82. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol (Endocrinol Metab) 1997; 273: E981-988
83. Lacroix A, Bolté E, Tremblay J, Dupré J, Poitras P, Fournier H et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's Syndrome. N Engl J Med 1992; 327: 974-980
84. Deacon CF, Pridal L, Klarskov L, Diesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol (Endocrinol Metab) 1996; 271: E458-E464
85. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202
86. Ross SA, Dupré J. Effects of ingestion of triglycéride orgalactose on secretion of Gastric Inhibitory Polypeptide and on response to intravenous glucose in normal and diabetic subjects. Diabetes 1978; 27: 327-333
87. Falko JM, Crockett SE, Cataland S, Mazzaferri EL. Gastric Inhibitory Polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab 1975; 41: 260-265
88. Ebert R, Frerichs H, Creutzfeldt W. Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance. Eur J Clin Invest 1979; 9: 129-135
89. Creutzfeldt W, Ebert R, Willms B, Frerichs H, Brown JC. Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels. Diabetologia 1978; 14: 15-24
90. Salera M, Giacomoni P, Pironi L, Cornia G, Capelli M, Marini A et al. Gastric inhibitory polypeptide release after oral glucose: Relationship to glucose intolerance, diabetes mellitus and obesity. J Clin Endocrinol Metab 1982; 55: 329-336
91. Elahi D, Andersen DK, Muller DC, Tobin JD, Brown JC, Andres R. The enteric enhancement of glucose-stimulated insulin release: the role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus. Diabetes 1984; 33: 950-957
92. Marks V. GIP-the obesity hormone. In: James WPT, Parker SW (eds.). Obesity, current approaches. Southampton: Duphar Medical Relations, 1988: 13-20
93. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103
94. Yip RGC, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology 1998; 139: 4004-4007
95. Knapper JM, Puddicombe SM, Morgan LM, Fletcher JM. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat adipose tissue. J Nutr 1995; 125: 183-188
96. Dupré J, Greenidge N, McDonald TJ, Ross SA, Rubinstein D. Inhibition of action of glucagon in adipocytes by gastric inhibitory polypeptide. Metabolism 1976; 25: 1197-1199
97. Ebert R, Nauck M, Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride response in rats. Horm Metab Res 1991; 23: 517-521
98. Ohneda A, Kobayashi T, Hihei J. Effect of enogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs. Regul Pept 1983; 6: 25-32
99. Jorde R, Pettersen JE, Burhol PG. Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of intralipid in man. Acta Med Scand 1984; 216: 19-23
100. Gault VA, O'Harte FP, Harriot P, Mooney MH, Green BD, Flatt PR. Effects of the novel (Pro(3))GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003; 46: 222-230
101. Service FJ, Rizza RA, Westland RE, Hall LD, Gerich JE, Go VLW. Gastric inhibitory polypeptide in obesity and diabetes mellitus. J Clin Endocrinol Metab 1984; 58: 1133-1140
102. Yki-Järvinen H, Taskinen MR, Kovisto VA, Nikkila EA. Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in men. Diabetologia 1984; 27: 364-369
103. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121
104. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 1996; 98: 2440-2445
105. Toumilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1349
106. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
107. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
108. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocrine Rev 1998; 19: 491-503
109. Gutniak MK, Holst JJ, Ørskov C, Åhren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322
110. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520
111. Zander M, Madsbad S, Holst JJ. GLP-1 for six weeks reduces body weight and improves insulin sensitivity and glycemic control in patients with Type 2 diabetes. Diabetes 2001; 50 (Suppl. 2): A31
112. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4630-4605
113. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455
114. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158
115. Starich GH, Bar RS, Mazzaferri EL. GIP increases insulin receptor affinity and cellular sensitivity in adipocytes. Am J Physiol 1985; 249: E603-E607
116. Hauner H, Glatting G, Kaminska D, Pfeiffer EF. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 1988; 32: 282-288
117. Kwasowski PK, Tan S, DeSilva MJ, Marks V. Increased chylomicronaemia in fed rats given gastric inhibitory polypeptide antibodies (abstract). Diabetologia 1984; 27: A300-A301
118. Meier JJ, Nauck MA. Glucose-dependent insulinotropic polypeptide/ gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab 2004; 18: 587-606